Patriot Financial Group Insurance Agency LLC Boosts Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Patriot Financial Group Insurance Agency LLC lifted its position in IQVIA Holdings Inc. (NYSE:IQV) by 21.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,752 shares of the medical research company’s stock after acquiring an additional 1,011 shares during the quarter. Patriot Financial Group Insurance Agency LLC’s holdings in IQVIA were worth $1,331,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. HighTower Advisors LLC boosted its position in IQVIA by 2.4% during the 1st quarter. HighTower Advisors LLC now owns 5,055 shares of the medical research company’s stock worth $1,168,000 after acquiring an additional 118 shares during the period. Prudential PLC acquired a new position in IQVIA during the 1st quarter worth $741,000. Baird Financial Group Inc. boosted its position in IQVIA by 2.3% during the 1st quarter. Baird Financial Group Inc. now owns 99,566 shares of the medical research company’s stock worth $23,021,000 after acquiring an additional 2,201 shares during the period. Parkside Financial Bank & Trust lifted its holdings in shares of IQVIA by 59.0% in the first quarter. Parkside Financial Bank & Trust now owns 388 shares of the medical research company’s stock valued at $90,000 after buying an additional 144 shares during the period. Finally, Covestor Ltd lifted its holdings in shares of IQVIA by 82.2% in the first quarter. Covestor Ltd now owns 554 shares of the medical research company’s stock valued at $128,000 after buying an additional 250 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Up 0.1 %

IQV stock traded up $0.32 during mid-day trading on Friday, hitting $252.89. The stock had a trading volume of 771,448 shares, compared to its average volume of 901,423. The company has a current ratio of 0.86, a quick ratio of 0.86 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 1-year low of $167.42 and a 1-year high of $261.73. The company has a fifty day moving average of $237.22 and a 200 day moving average of $218.02. The stock has a market capitalization of $45.90 billion, a price-to-earnings ratio of 34.69, a PEG ratio of 2.44 and a beta of 1.51.

IQVIA (NYSE:IQV) last issued its earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share for the quarter, topping the consensus estimate of $2.82 by $0.02. IQVIA had a return on equity of 29.32% and a net margin of 9.06%. The company had revenue of $3.87 billion for the quarter, compared to analyst estimates of $3.80 billion. During the same period in the prior year, the firm posted $2.54 EPS. The business’s revenue was up 3.5% compared to the same quarter last year. On average, equities analysts expect that IQVIA Holdings Inc. will post 10.11 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Eric Sherbet sold 1,000 shares of the stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $241.50, for a total transaction of $241,500.00. Following the transaction, the insider now owns 20,836 shares of the company’s stock, valued at approximately $5,031,894. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, insider Eric Sherbet sold 1,000 shares of the stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $241.50, for a total transaction of $241,500.00. Following the completion of the sale, the insider now owns 20,836 shares in the company, valued at approximately $5,031,894. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Ari Bousbib sold 31,678 shares of the stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $250.53, for a total value of $7,936,289.34. Following the sale, the insider now owns 796,752 shares of the company’s stock, valued at approximately $199,610,278.56. The disclosure for this sale can be found here. Insiders have sold a total of 41,285 shares of company stock valued at $10,331,003 in the last three months. Insiders own 1.60% of the company’s stock.

Wall Street Analysts Forecast Growth

IQV has been the subject of several research analyst reports. BTIG Research initiated coverage on IQVIA in a report on Tuesday, February 13th. They issued a “buy” rating and a $285.00 price objective for the company. Citigroup upped their price objective on IQVIA from $190.00 to $225.00 and gave the company a “neutral” rating in a report on Monday, December 11th. SVB Leerink began coverage on IQVIA in a report on Monday, February 26th. They issued an “outperform” rating and a $290.00 price objective for the company. StockNews.com raised IQVIA from a “hold” rating to a “buy” rating in a report on Friday, February 16th. Finally, Evercore ISI upped their target price on IQVIA from $255.00 to $265.00 and gave the company a “market outperform” rating in a report on Thursday, February 15th. Three analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and an average price target of $256.80.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.